Biogen Reports Q1 Revenue of $2.48B, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy BIIB?
Reports Q1 revenue $2.48B, consensus $2.25B. President and Chief Executive Officer Christopher Viehbacher said: "We significantly advanced our transformation into the New Biogen through strong commercial and pipeline execution and the announcement of our intent to acquire Apellis. We believe the planned acquisition of Apellis will bolster our revenue and earnings growth, adding two differentiated commercial medicines and deepening the foundation for felzartamab, our key Phase 3 asset in kidney disease. This acquisition and the acquired rights to felzartamab in China come while we also expanded sales of our growth products, demonstrated continued resilience in our MS portfolio and reported important positive new data that reinforce our confidence in the late-stage pipeline."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 191.380
Low
143.00
Averages
204.45
High
246.00
Current: 191.380
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen and Eisai FDA Review Extended
- FDA Review Extension: Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) has extended the review period for their new drug application, with the specific duration of the extension yet to be disclosed, which may impact the drug's market launch timeline and investor expectations.
- Potential Market Reaction: The extension of the FDA review could lead to short-term volatility in the stock prices of Biogen and Eisai, particularly given the high market anticipation surrounding the new drug's approval.
- R&D Progress Uncertainty: This review extension may indicate that the FDA has further concerns regarding the drug's safety or efficacy, potentially requiring additional data, which could affect the companies' R&D timelines and resource allocation.
- Need for Strategic Adjustment: In light of the FDA review extension, Biogen and Eisai may need to reassess their market strategies and R&D directions to ensure they maintain a competitive edge in the rapidly evolving biopharmaceutical market.
See More
FDA Extends LEQEMBI Review Period
- Review Extension: The FDA has extended the review period for LEQEMBI as a starting dose for early Alzheimer's disease treatment by three months, with the new PDUFA action date set for August 24, 2026, indicating ongoing regulatory scrutiny.
- Additional Information Request: During the review process, the FDA requested further information but raised no concerns regarding the drug's approvability, suggesting a positive outlook for LEQEMBI's market potential.
- International Approval Status: LEQEMBI has been approved in over 50 countries for the treatment of early Alzheimer's disease, reflecting its broad acceptance and potential commercial value in the global market.
- Market Impact Analysis: This review extension may influence Eisai and Biogen's market strategies, particularly regarding the anticipated launch timeline, necessitating adjustments in their marketing plans to align with the new schedule.
See More
FDA Extends Review Period for Leqembi IQLIK Injection
- Review Period Extension: The FDA has announced a three-month extension for the review of the supplemental application for Leqembi IQLIK subcutaneous injection, with the new PDUFA date set for August 24, 2026, indicating the agency's commitment to thorough evaluation.
- Additional Information Request: As part of the review process, the FDA requested additional information, classifying it as a major amendment to the sBLA, which allows sufficient time for a comprehensive review of the new materials, ensuring data integrity.
- Optimistic Approval Outlook: To date, the FDA has not raised any concerns regarding the approvability of Leqembi IQLIK as an initial treatment option for early Alzheimer's disease, suggesting a favorable market outlook for the drug.
- Market Impact Analysis: The collaboration between Biogen and Eisai is particularly significant in this context, as it is expected to positively influence future revenues and market share, especially in the competitive landscape of Alzheimer's disease treatments.
See More
FDA Extends LEQEMBI Review Period by Three Months
- Review Period Extension: The FDA has extended the review period for LEQEMBI's supplemental Biologics License Application by three months, with a new action date set for August 24, 2026, allowing for a thorough review of additional materials, which may impact the drug's market entry timeline.
- Clinical Data Support: Eisai and Biogen assert that the comprehensive clinical data package for LEQEMBI strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which, if approved, would provide patients with more treatment options and enhance market competitiveness.
- Global Regulatory Confidence: LEQEMBI has been approved by over 50 regulatory authorities worldwide, reflecting broad confidence in its efficacy as a treatment option for early Alzheimer's disease, which will help bolster the companies' reputations and sales potential in the global market.
- Safety Concerns: In clinical trials, the incidence of ARIA with LEQEMBI was reported at 21% compared to 9% for placebo, indicating the need for enhanced monitoring and risk management strategies during its rollout to ensure patient safety and minimize adverse reactions.
See More
FDA Extends LEQEMBI Review Period by Three Months
- Review Period Extension: The FDA has extended the review period for LEQEMBI's supplemental Biologics License Application by three months, with a new action date set for August 24, 2026, indicating the agency's significant attention to the drug.
- Data Support: Eisai and Biogen believe that the comprehensive clinical data package for LEQEMBI strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which is expected to provide patients with more treatment options.
- Global Recognition: LEQEMBI has been approved by over 50 regulatory authorities worldwide, reflecting broad confidence in its efficacy as a treatment option for early Alzheimer's disease, thereby enhancing its competitive position in the market.
- Risk Management: The FDA has not raised any concerns regarding the approvability of LEQEMBI during the review process, and Eisai and Biogen are committed to ongoing discussions with the FDA to expedite the delivery of this important advancement to patients.
See More
Eli Lilly Reports Strong Q1 Performance with Revenue Surge
- Significant Revenue Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase that surpassed the market expectation of $17.6 billion, demonstrating strong performance in the obesity drug market and reinforcing investor confidence in the stock.
- Earnings Surge: Adjusted earnings per share reached $8.55, more than doubling from last year and exceeding the consensus estimate of $6.66, indicating the company's ability to achieve profitability despite declining drug prices.
- Competitive Market Dynamics: Despite competition from Novo Nordisk, CEO David Ricks emphasized that the company can overcome price declines through higher volumes, with U.S. drug prices down 7% but volumes up 49%, showcasing strong demand for its GLP-1 products.
- New Drug Launch and Market Outlook: The recently launched obesity drug Foundayo received FDA approval and became available quickly; although initial growth has been slow, 80% of prescriptions are from patients who had not previously used GLP-1 drugs, suggesting potential to expand the market size.
See More
Biogen and Eisai FDA Review Extended
- FDA Review Extension: Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) has extended the review period for their new drug application, with the specific duration of the extension yet to be disclosed, which may impact the drug's market launch timeline and investor expectations.
- Potential Market Reaction: The extension of the FDA review could lead to short-term volatility in the stock prices of Biogen and Eisai, particularly given the high market anticipation surrounding the new drug's approval.
- R&D Progress Uncertainty: This review extension may indicate that the FDA has further concerns regarding the drug's safety or efficacy, potentially requiring additional data, which could affect the companies' R&D timelines and resource allocation.
- Need for Strategic Adjustment: In light of the FDA review extension, Biogen and Eisai may need to reassess their market strategies and R&D directions to ensure they maintain a competitive edge in the rapidly evolving biopharmaceutical market.
See More
FDA Extends LEQEMBI Review Period
- Review Extension: The FDA has extended the review period for LEQEMBI as a starting dose for early Alzheimer's disease treatment by three months, with the new PDUFA action date set for August 24, 2026, indicating ongoing regulatory scrutiny.
- Additional Information Request: During the review process, the FDA requested further information but raised no concerns regarding the drug's approvability, suggesting a positive outlook for LEQEMBI's market potential.
- International Approval Status: LEQEMBI has been approved in over 50 countries for the treatment of early Alzheimer's disease, reflecting its broad acceptance and potential commercial value in the global market.
- Market Impact Analysis: This review extension may influence Eisai and Biogen's market strategies, particularly regarding the anticipated launch timeline, necessitating adjustments in their marketing plans to align with the new schedule.
See More
FDA Extends Review Period for Leqembi IQLIK Injection
- Review Period Extension: The FDA has announced a three-month extension for the review of the supplemental application for Leqembi IQLIK subcutaneous injection, with the new PDUFA date set for August 24, 2026, indicating the agency's commitment to thorough evaluation.
- Additional Information Request: As part of the review process, the FDA requested additional information, classifying it as a major amendment to the sBLA, which allows sufficient time for a comprehensive review of the new materials, ensuring data integrity.
- Optimistic Approval Outlook: To date, the FDA has not raised any concerns regarding the approvability of Leqembi IQLIK as an initial treatment option for early Alzheimer's disease, suggesting a favorable market outlook for the drug.
- Market Impact Analysis: The collaboration between Biogen and Eisai is particularly significant in this context, as it is expected to positively influence future revenues and market share, especially in the competitive landscape of Alzheimer's disease treatments.
See More
FDA Extends LEQEMBI Review Period by Three Months
- Review Period Extension: The FDA has extended the review period for LEQEMBI's supplemental Biologics License Application by three months, with a new action date set for August 24, 2026, allowing for a thorough review of additional materials, which may impact the drug's market entry timeline.
- Clinical Data Support: Eisai and Biogen assert that the comprehensive clinical data package for LEQEMBI strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which, if approved, would provide patients with more treatment options and enhance market competitiveness.
- Global Regulatory Confidence: LEQEMBI has been approved by over 50 regulatory authorities worldwide, reflecting broad confidence in its efficacy as a treatment option for early Alzheimer's disease, which will help bolster the companies' reputations and sales potential in the global market.
- Safety Concerns: In clinical trials, the incidence of ARIA with LEQEMBI was reported at 21% compared to 9% for placebo, indicating the need for enhanced monitoring and risk management strategies during its rollout to ensure patient safety and minimize adverse reactions.
See More
FDA Extends LEQEMBI Review Period by Three Months
- Review Period Extension: The FDA has extended the review period for LEQEMBI's supplemental Biologics License Application by three months, with a new action date set for August 24, 2026, indicating the agency's significant attention to the drug.
- Data Support: Eisai and Biogen believe that the comprehensive clinical data package for LEQEMBI strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which is expected to provide patients with more treatment options.
- Global Recognition: LEQEMBI has been approved by over 50 regulatory authorities worldwide, reflecting broad confidence in its efficacy as a treatment option for early Alzheimer's disease, thereby enhancing its competitive position in the market.
- Risk Management: The FDA has not raised any concerns regarding the approvability of LEQEMBI during the review process, and Eisai and Biogen are committed to ongoing discussions with the FDA to expedite the delivery of this important advancement to patients.
See More
Eli Lilly Reports Strong Q1 Performance with Revenue Surge
- Significant Revenue Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase that surpassed the market expectation of $17.6 billion, demonstrating strong performance in the obesity drug market and reinforcing investor confidence in the stock.
- Earnings Surge: Adjusted earnings per share reached $8.55, more than doubling from last year and exceeding the consensus estimate of $6.66, indicating the company's ability to achieve profitability despite declining drug prices.
- Competitive Market Dynamics: Despite competition from Novo Nordisk, CEO David Ricks emphasized that the company can overcome price declines through higher volumes, with U.S. drug prices down 7% but volumes up 49%, showcasing strong demand for its GLP-1 products.
- New Drug Launch and Market Outlook: The recently launched obesity drug Foundayo received FDA approval and became available quickly; although initial growth has been slow, 80% of prescriptions are from patients who had not previously used GLP-1 drugs, suggesting potential to expand the market size.
See More
